| 18 Octobre 2016
The affiliate office in Côte d’Ivoire will serve as regional hub for Merck’s operations in French speaking countries in Central and West Africa
ABIDJAN, Côte d’Ivoire, October 17, 2016
The affiliate office in Côte d’Ivoire will serve as regional hub for Merck’s operations in French speaking countries in Central and West Africa
The German science and technology company donated 2 minilabs to Côte d’Ivoire supporting their fight against counterfeit medicines
Merck (http://www.MerckGroup.com),  a leading science and technology company, today announced the opening  of its affiliate office in Abidjan, Côte d’Ivoire, which will serve as  the regional hub for the company’s operations in French-speaking Central  and West African countries.
“For several years, Côte d’Ivoire  has shown continuous growth, as well as economic, political and social  stability. The main driver of this achievement being its increase in  competitiveness and steady progress in economic development,(1)” Dr.  Frank Stangenberg-Haverkamp, Chairman of the Executive Board and the  Family Board of E. Merck KG, said at the opening. “We are excited to  open this office in Abidjan, which will be our first in Francophone  Sub-Saharan Africa.”
The office was inaugurated by his  Excellency, the Ambassador of the Federal Republic of Germany to Côte  d'Ivoire, Dr. Claus Auer and key representatives of the Ivorian  government along with Dr. Stangenberg-Haverkamp and Dr. Karim Bendhaou,  President of North & West Africa.
“This new office will allow  us to reinforce and to develop our already existing activities in the  country and it will be the hub for French speaking countries in Central  and West Africa. We will continue to bring specialist and high-quality  products to serve patients and help them to improve their quality of  life,” added Dr. Bendhaou.
Merck also donated two minilabs with  the aim of supporting Côte d’Ivoire in its fight against counterfeit  medicines. The minilabs, which help to detect counterfeits, are  manufactured by the Global Pharma Health Fund (GPHF), a charitable  initiative financed by Merck.
“We are pleased that our plan to  establish a public-private partnership to combat counterfeits will be  translated into effective measures with the donated minilabs, in  addition to an awareness campaign led by the Minister of Health and  Public Hygiene,” Bendhaou said. The donation ceremony was graced by The  First Lady of Côte d’Ivoire, Dominique Claudine Ouattara and H.E.  Minister of Health and Public Hygiene, Dr. Raymonde Goudou Coffie. These  minilabs will be the first to be used in Côte d’Ivoire.
“This  donation done by Merck will allow us to reinforce our structures for  drug monitoring. The people will be reassured that they are investing in  medicines which are safe, not dangerous and suitable for consumption,”  H.E. Minister of Health and Public Hygiene expressed her gratitude for  this donation. “The mobile compact laboratories are globally renowned  for their ability to detect counterfeits quickly, cost-efficiently and  reliably. The Ministry of Health and Public Hygiene makes quality  control its top priority.”
Merck’s fight against counterfeit  medicines is part of the company’s health-related corporate  responsibility initiatives. Many people in low- to middle-income  countries lack access to high-quality health solutions and Merck is  leveraging its expertise and collaborating with strong partners to  develop innovative solutions for such patients.
(1) “Lions on the Move II: Realizing the potential of Africa’s Economies” McKinsey Global Institute, Sept. 2016
About Merck 
Merck (http://www.MerckGroup.com)  is a leading science and technology company in healthcare, life science  and performance materials. Around 50,000 employees work to further  develop technologies that improve and enhance life – from  biopharmaceutical therapies to treat cancer or multiple sclerosis,  cutting-edge systems for scientific research and production, to liquid  crystals for smartphones and LCD televisions. In 2015, Merck generated  sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck is  the world's oldest pharmaceutical and chemical company. The founding  family remains the majority owner of the publicly listed corporate  group. Merck holds the global rights to the Merck name and brand. The  only exceptions are the United States and Canada, where the company  operates as EMD Serono, MilliporeSigma and EMD Performance Materials.









